Digital health assistant to improve cholesterol medication adherence
AdLip: Use of Human Coach-supported Digital/AI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications: a Multi-centre Randomised Controlled Trial
This study tests whether a digital health assistant with human support can help people with high cholesterol remember to take their medication regularly.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 450 (estimated) |
| Ages | 21 Years to 84 Years |
| Sex | All |
| Sponsor | National University of Singapore Academic / other |
| Locations | 2 sites (Singapore and 1 other locations) |
| Trial ID | NCT06614049 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of a human coach-supported digital and AI personal health assistant in enhancing adherence to cholesterol-lowering medications among patients with hyperlipidemia. The intervention aims to address the significant issue of medication non-adherence, which affects around 60% of adults in Singapore. By utilizing digital technology, the study seeks to provide timely reminders and relevant information to encourage patients to take their medications as prescribed. The approach is compared to standard care to evaluate its impact on medication adherence and overall health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are Singapore residents aged 21 to 84 who have been prescribed statins and exhibit medication non-adherence.
Not a fit: Patients who are currently using other smartphone medication adherence apps or have severe renal or liver diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve medication adherence and health outcomes for patients with hyperlipidemia.
How similar studies have performed: Other studies have shown promising results using digital interventions to improve medication adherence, indicating that this approach is supported by existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between 21 to 84 years old * Prescribed statins with or without ezetimibe for hyperlipidaemia. * Medication non-adherence as defined by the \"Extent to Non-adherence\" sub-scale of the DOSE Non-Adherence Measure), with a score \> 1 (range from 0-15) * Singapore residents (citizens, permanent residents, or long-term pass holders). * In possession of a smartphone or tablet with Android or iOS operating systems. * Have internet access on their mobile devices. Exclusion Criteria: * Does not read or understand English. Current use of smartphone medication adherence app(s) that include statins. * Concurrent use of PCSK9 Inhibitors in addition to statins and/or ezetimibe * Participation in another study that uses medications that could affect lipid levels * Severe renal impairment defined as chronic kidney disease stage 4 and above. * Severe liver disease (Child-Pugh Class C) * Existing muscular-related complaints or diagnoses which may confound adverse event reporting * Uncorrected thyroid conditions, especially poorly-controlled hypothyroidism * Documented psychiatric diagnosis or history of mental illness or deemed as unable to give informed consent. * Currently pregnant, breastfeeding or expecting to get pregnant during the course of the study (1 year). * Guarded prognosis with expectant mortality within 12 months or less.
Where this trial is running
Singapore and 1 other locations
- National Healthcare Group Polyclinics — Singapore, Singapore (Recruiting)
- National University Polyclinics — Singapore, Singapore (Recruiting)
Study contacts
- Principal investigator: Ying Xian Chua — National University Polyclinics
- Study coordinator: Doreen Su-Yin Tan, Pharm.D.
- Email: doreen.tan.sy@nus.edu.sg
- Phone: 66016471
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.